Short description
Rege Nephro is a biotech company that specialized in R&D, production and marketing of renal disease therapeutics.
Description
Rege Nephro is involved in the development, production, and sale of renal disease drugs.
Rege Nephro, a Kyoto University biotech venture, successfully achieved stable production of nephron progenitor cells by using technology developed by Kyoto University Professor Kenji Osafune to efficiently differentiate nephron progenitor cells from iPSCs. Rege Nephro is currently investigating and developing regenerative medicine products for kidney diseases using these cells, as well as producing kidney organoids*2 capable of nephrotoxicity screening for drug discovery in applied research.
Last funding
Cannot Access
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Kyoto, Kyoto, Japan, Asia
Founded on
September 20, 2019
Non-profit?
No
Acquired?
No
Employees count
11-50
Investors
Absolutely Noaccess, Noaccessforu, Noaccessforu, Absolutely Noaccess, Uh Ohhhh, Nopepepe, Cannot Access, Noaccess, Nopepepe, Nopepepe, No Way, Uh Ohhhh, Noaccess
Sign in for full access
Founders
Kenji Osafune